BioOrbit develops compact, modular autonomous manufacturing units called BOX to perform crystallisation of biological drugs in microgravity at industry-relevant scale. The company positions BOX as a microwave-sized payload that moves crystallisation from one-off experiments to repeatable manufacturing pathways not achievable on Earth. BioOrbit says its technology enables better-performing biologics and is engaging with the NHS and the UK Space Agency while working on regulatory pathways with the MHRA, Regulatory Innovation Office and CAA. The company was founded and funded by Dr. Katie King and co-founder oncology researcher Dr. Leonor Teles and has appointed senior pharma-and-space executives to its leadership team. BioOrbit has participated in accelerators including Airbus Accelerator, Seraphim Space Accelerator, ESA BSGN Life Sciences, ESA BIC UK and the UK Space Agency LEO Accelerator. The articles do not disclose current revenue or user metrics.

Total raised

$13M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026